Oncternal Therapeutics (NASDAQ:ONCT) PT Lowered to $28.00 at HC Wainwright

Oncternal Therapeutics (NASDAQ:ONCT – Free Report) had its target price decreased by HC Wainwright from $30.00 to $28.00 in a report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q1 2024 earnings at ($3.30) EPS, Q2 2024 earnings at […]

Related Keywords

,Mirabella Financial Services ,Prudential Financial Inc ,Susquehanna International Group ,Oncternal Therapeutics Inc ,Virtu Financial ,Citadel Advisors ,Oncternal Therapeutics ,Free Report ,Get Free Report ,Director Robert James Wills ,Financial Services ,Orphan Receptor ,Oncternal Therapeutics Daily ,Nasdaq Onct ,Conct ,Medical ,Lower Price Target ,Hc Wainwright ,